🇺🇸 Paritaprevir/ritonavir/ombitasvir in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 18

Most-reported reactions

1. Treatment Failure — 5 reports (27.78%)
2. Haemoglobin Decreased — 4 reports (22.22%)
3. Hepatic Failure — 2 reports (11.11%)
4. Acute Kidney Injury — 1 report (5.56%)
5. Anaemia — 1 report (5.56%)
6. Ascites — 1 report (5.56%)
7. Chronic Hepatic Failure — 1 report (5.56%)
8. Drug-Induced Liver Injury — 1 report (5.56%)
9. Encephalopathy — 1 report (5.56%)
10. Fatigue — 1 report (5.56%)

Source database →

Frequently asked questions

Is Paritaprevir/ritonavir/ombitasvir approved in United States?

Paritaprevir/ritonavir/ombitasvir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Paritaprevir/ritonavir/ombitasvir in United States?

AbbVie is the originator. The local marketing authorisation holder may differ — check the official source linked above.